Figure 3.
Affinity attenuation of the HER-2 and CD3 arms of HER-2/CD3 IgG BsAb. (A) Biosensor kinetics demonstrating an approximately sevenfold and ninefold affinity reduction of the pertuzumab arm binding to soluble human HER-2 antigen. The exact attenuating mutations are listed in the top left corner. (B) The impact of CD3 attenuating mutations within the IgG BsAb was measured using competition FACS displacement of a wild-type SP34 monoclonal antibody labeled with phycoerythrin. BsAb, bispecific antibody.